


Product Datasheet



Mouse Anti-Factor VII

Overview

Product number	PDZMM135
Host species	Mouse
Target species	Human
Suitable for:	IHC-P, WB, ELISA, Immunomicroscopy, Dot blot, ICC, IHC-Fr
Immunogen	A KLH-conjugated recombinant factor VII (NovoSeven) was used for immunization.

Conjugation Unconjugated

Properties

Form Liquid

Storage instructions Shipped at 4 °C. Store at -20 °C. Avoid freeze/thaw cycle. Please see notes section.

Storage buffer pH: 7.4, Preservative: Stabilizer, Constituents: PBS 0.01mM

Purity immunogen affinity or SpG purified

Purification notes This product was prepared by immunoaffinity chromatography using immunogen peptide coupled to Sepharose 4B.

Conjugation notes -

Clonality Monoclonal

Isotype IgG

General notes For extended storage aliquot contents and freeze at -20 °C or below. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4 °C as an undiluted liquid. Dilute only prior to immediate use.

Our customer's feedback says the antibody worked great. In case the antibody fails to give results then please contact our scientific support team for assistance.

Applications

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end-user.

Product Usage Information:

Application Dilutions

Western Blotting	3-5 ug/ml
Immunohistochemistry (Paraffin)	5-10 ug/ml
Immunohistochemistry (Frozen)	5-10 ug/ml
Immunofluorescence	5-10 ug/ml
Flow Cytometry	5-10 ug/ml

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Background:

Factor VII (EC 3.4.21.21, blood-coagulation factor VIIa, activated blood coagulation factor VII, formerly known as proconvertin) is one of the proteins that causes blood to clot in the coagulation cascade. It is an enzyme of the serine protease class. A recombinant form of human factor VIIa (eptacog alfa [activated], NovoSeven) has U.S. Food and Drug Administration approval for uncontrolled bleeding in hemophilia patients. It is sometimes used unlicensed in severe uncontrollable bleeding, although there have been safety concerns. A biosimilar form of recombinant activated factor VII (AryoSeven) is also available, but does not play any considerable role in the market.

Terms and conditions

Guarantee only valid for products bought direct from PADZA or one of our authorized distributors

References:

Note: This product has originally been developed at Avicenna Research Institute, Tehran, IRAN and assigned to PADZA Company according to contract 98/15/191dated 98/01/10.